Business
Health Sciences Acquisitions Corporation and Immunovant to Host Joint Conference Call for the Investment Community on Friday, October 11, at 8:30am EDT
NEW YORK and LONDON, Oct. 8, 2019 /PRNewswire/ -- Health Sciences Acquisitions Corporation ("HSAC," NASDAQ: HSAC), a special purpose acquisition company
About this update from Immunovant, Inc.
[{"type":"text","content":" NEW YORK and LONDON, Oct. 8, 2019 /PRNewswire/ -- Health Sciences Acquisitions Corporation (\"HSAC,\" NASDAQ: HSAC), a special purpose acquisition company sponsored by RTW Investments, and Immunovant Sciences Ltd. (\"Immunovant\"), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced that they will host a joint conference call to discuss their planned merger. The conference call will take place on Friday, October 11, at 8:30am EDT. Following prepared remarks, the call will include a question-and-answer session for the investment community.\nTo access the webcast, please visit Immunovant's website at www.immunovant.com. Participants may also dial in using the numbers provided below. When prompted, participants should request to join the \"HSAC and Immunovant Conference Call.\" \nToll Free: 1-877-407-9039Toll/International: 1-201-689-8470 \nFollowing the webcast, an archived version of the call will be available for 6 months at www.immunovant.com.\nAbout Immunovant \nImmunovant, a member of the Roivant family of companies, is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. For further information about Immunovant, please visit www.immunovant.com.\nAbout Roivant\nRoivant Sciences aims to improve health by rapidly delivering innovative medicines and technologies to patients. Roivant does this by building Vants – nimble, entrepreneurial biotech, and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization. For further information about Roivant, please visit www.roivant.com.\nAbout Health Sciences Acquisitions Corporation\nHSAC is a Delaware company established for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. On May 14, 2019, HSAC raised $115 million to achieve this goal. As of June 30, 2019, there was approximately $115.3 milli...